An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancerResearch in context

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancerResearch in context

Background: KRAS mutations are the most frequent oncogenic aberration in lung adenocarcinoma. KRAS mutant isoforms differentially shape tumour biology and influence drug responses. This heterogeneity challenges the development of effective therapies for patients with KRAS-driven non-small cell lung...

Full description

Bibliographic Details
Main Authors:	Haiyun Wang, Qi Lv, Yue Xu, Zhaoqing Cai, Jie Zheng, Xiaojie Cheng, Yao Dai, Pasi A. Jänne, Chiara Ambrogio, Jens Köhler
Format:	Article
Language:	English
Published:	Elsevier 2019-11-01
Series:	EBioMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396419306760

Similar Items

If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for <i>KRAS</i>-Mutant Lung Cancer
by: Jens Köhler, et al.
Published: (2021-03-01)

Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancerResearch in context
by: Xiaoyu Liu, et al.
Published: (2019-03-01)

Dissecting the genetic heterogeneity of gastric cancerResearch in context
by: Timo Hess, et al.
Published: (2023-06-01)

Metabolic syndrome is linked to the incidence of pancreatic cancerResearch in context
by: Yohei Miyashita, et al.
Published: (2024-01-01)

The Landscape and Implications of Chimeric RNAs in Cervical CancerResearch in context
by: Peng Wu, et al.
Published: (2018-11-01)

Plasma protein biomarkers for early prediction of lung cancerResearch in context
by: Michael P.A. Davies, et al.
Published: (2023-07-01)

Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinomaResearch in context
by: Ke Liu, et al.
Published: (2018-10-01)

The prognostic landscape of interactive biological processes presents treatment responses in cancerResearch in context
by: Bin He, et al.
Published: (2019-03-01)

Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancerResearch in context
by: Lihui Li, et al.
Published: (2019-07-01)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
by: Yuta Adachi, et al.
Published: (2021-10-01)

Therapeutic Approach of KRAS Mutant Tumours by the Combination of Pharmacologic Ascorbate and Chloroquine
by: Orsolya Kapuy, et al.
Published: (2021-04-01)

Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy
by: Gemma Bruera, et al.
Published: (2020-08-01)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
by: Ke Xu, et al.
Published: (2019-04-01)

Pharmacogenomics in clinical therapeutics /
by: Langman, Loralie J. 536145, et al.
Published: (2012)

Genomic characteristics and immune landscape of super multiple primary lung cancerResearch in context
by: Zhenlin Yang, et al.
Published: (2024-03-01)

Distinct intratumoral microbiome of young-onset and average-onset colorectal cancerResearch in context
by: Shimoli V. Barot, et al.
Published: (2024-02-01)

The association between genetically elevated polyunsaturated fatty acids and risk of cancerResearch in context
by: Philip C. Haycock, et al.
Published: (2023-05-01)

Non-canonical role of UCKL1 on ferroptosis defence in colorectal cancerResearch in context
by: Weili Wu, et al.
Published: (2023-07-01)

Inhibition of LTA4H by bestatin in human and mouse colorectal cancerResearch in context
by: Simin Zhao, et al.
Published: (2019-06-01)

Osteoglycin-induced VEGF Inhibition Enhances T Lymphocytes Infiltrating in Colorectal CancerResearch in Context
by: Xiang Hu, et al.
Published: (2018-08-01)

Radiomics signature of computed tomography imaging for prediction of survival and chemotherapeutic benefits in gastric cancerResearch in context
by: Yuming Jiang, et al.
Published: (2018-10-01)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
by: Xiufeng Pang, et al.
Published: (2016-10-01)

KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
by: Saveri Bhattacharya, et al.
Published: (2015-12-01)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
by: Ke Xu, et al.
Published: (2020-05-01)

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancerResearch in context
by: Andrew A. Davis, et al.
Published: (2022-12-01)

Urine proteomic signatures predicting the progression from premalignancy to malignant gastric cancerResearch in context
by: Hua Fan, et al.
Published: (2022-12-01)

MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancerResearch in context
by: Jingyan Yi, et al.
Published: (2019-05-01)

Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy.
by: Xin Dai, et al.
Published: (2015-01-01)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
by: Nicolas Bery, et al.
Published: (2020-06-01)

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
by: Nastaran Karimi, et al.
Published: (2023-02-01)

Mitochondrial fission factor is a novel Myc-dependent regulator of mitochondrial permeability in cancerResearch in context
by: Jae Ho Seo, et al.
Published: (2019-10-01)

Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancerResearch in context
by: Patrice Hodonou Avogbe, et al.
Published: (2019-06-01)

Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
by: Kushtrim Kryeziu, et al.
Published: (2021-09-01)

Small molecular inhibitors for KRAS-mutant cancers
by: Xuan Wu, et al.
Published: (2023-08-01)

In silico analysis of wild-type and mutant KRAS
by: Frengki Frengki, et al.
Published: (2019-05-01)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
by: Elisa Baldelli, et al.
Published: (2021-09-01)

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution
by: Grace R. Anderson, et al.
Published: (2017-07-01)

Single-cell RNA sequencing highlights the functional role of human endogenous retroviruses in gallbladder cancerResearch in context
by: Jinghan Wang, et al.
Published: (2022-11-01)

Fatty acid 2-hydroxylation inhibits tumor growth and increases sensitivity to cisplatin in gastric cancerResearch in context
by: Yizhou Yao, et al.
Published: (2019-03-01)

Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancerResearch in context
by: Rahat Jahan, et al.
Published: (2019-04-01)